Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23N3O2 |
| Molecular Weight | 349.4262 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCN1C(=O)\C(=N/NC(=O)C2=CC=CC=C2)C3=CC=CC=C13
InChI
InChIKey=ZGQHMZCITJHYOW-QOCHGBHMSA-N
InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14H,2-4,10,15H2,1H3,(H,23,25)/b22-19-
| Molecular Formula | C21H23N3O2 |
| Molecular Weight | 349.4262 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P21554|||Q5UB37 Gene ID: 1268.0 Gene Symbol: CNR1 Target Organism: Homo sapiens (Human) |
162.0 nM [Ki] | ||
Target ID: P34972 Gene ID: 1269.0 Gene Symbol: CNR2 Target Organism: Homo sapiens (Human) |
43.0 nM [Ki] | ||
Target ID: P20272 Gene ID: 25248.0 Gene Symbol: Cnr1 Target Organism: Rattus norvegicus (Rat) |
1.13 µM [Ki] | ||
Target ID: Q9QZN9 Gene ID: 57302.0 Gene Symbol: Cnr2 Target Organism: Rattus norvegicus (Rat) |
16.0 nM [Ki] |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:21:53 GMT 2025
by
admin
on
Mon Mar 31 23:21:53 GMT 2025
|
| Record UNII |
X83OI5CX2U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-MDA-19
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MDA-19
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
PRIMARY | MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects. | ||
|
X83OI5CX2U
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
PRIMARY | |||
|
135743701
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
PRIMARY | |||
|
MDA-19
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
PRIMARY | CB2 receptor agonist. Displays 4-fold higher affinity for the human CB2 receptor than the human CB1 receptor (Ki values are 43.3 and 162.4 nM respectively) shows 70-fold affinity for the rat CB2 receptor over the rat CB1 receptor (Ki values are 16.3 and 1130 nM respectively). Attenuates tactile allodynia in a rat model does not affect rat locomotor activity. | ||
|
1104302-26-2
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
1048973-47-2
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
PRIMARY | |||
|
DTXSID201029871
Created by
admin on Mon Mar 31 23:21:53 GMT 2025 , Edited by admin on Mon Mar 31 23:21:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
